Literature DB >> 19509467

Patients with lung cancer and paraneoplastic Hu syndrome harbor HuD-specific type 2 CD8+ T cells.

Wendy K Roberts1, Ilana J Deluca, Ashby Thomas, John Fak, Travis Williams, Noreen Buckley, Athanasios G Dousmanis, Jerome B Posner, Robert B Darnell.   

Abstract

Paraneoplastic neurologic disorders (PNDs) offer an uncommon opportunity to study human tumor immunity and autoimmunity. In small cell lung cancer (SCLC), expression of the HuD neuronal antigen is thought to lead to immune recognition, suppression of tumor growth, and, in a subset of patients, triggering of the Hu paraneoplastic neurologic syndrome. Antigen-specific CTLs believed to contribute to disease pathophysiology were described 10 years ago in paraneoplastic cerebellar degeneration. Despite parallel efforts, similar cells have not been defined in Hu patients. Here, we have identified HuD-specific T cells in Hu patients and provided an explanation for why their detection has been elusive. Different Hu patients harbored 1 of 2 kinds of HuD-specific CD8+ T cells: classical IFN-gamma-producing CTLs or unusual T cells that produced type 2 cytokines, most prominently IL-13 and IL-5, and lacked cytolytic activity. Further, we found evidence that SCLC tumor cells produced type 2 cytokines and that these cytokines trigger naive CD8+ T cells to adopt the atypical type 2 phenotype. These observations demonstrate the presence of an unusual noncytotoxic CD8+ T cell in patients with the Hu paraneoplastic syndrome and suggest that SCLC may evade tumor immune surveillance by skewing tumor antigen-specific T cells to this unusual noncytolytic phenotype.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19509467      PMCID: PMC2701858          DOI: 10.1172/JCI36131

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  39 in total

1.  cdr2-specific CTLs are detected in the blood of all patients with paraneoplastic cerebellar degeneration analyzed.

Authors:  R B Darnell; M L Albert
Journal:  Ann Neurol       Date:  2000-08       Impact factor: 10.422

2.  Tumor progression and serum anti-HuD antibody concentration in patients with paraneoplastic neurological syndromes.

Authors:  Sebastian Rauer; Ioanna Andreou
Journal:  Eur Neurol       Date:  2002       Impact factor: 1.710

3.  Observing the invisible: successful tumor immunity in humans.

Authors:  Robert B Darnell; Jerome B Posner
Journal:  Nat Immunol       Date:  2003-03       Impact factor: 25.606

Review 4.  Paraneoplastic syndromes involving the nervous system.

Authors:  Robert B Darnell; Jerome B Posner
Journal:  N Engl J Med       Date:  2003-10-16       Impact factor: 91.245

5.  H-2 class I knockout, HLA-A2.1-transgenic mice: a versatile animal model for preclinical evaluation of antitumor immunotherapeutic strategies.

Authors:  H Firat; F Garcia-Pons; S Tourdot; S Pascolo; A Scardino; Z Garcia; M L Michel; R W Jack; G Jung; K Kosmatopoulos; L Mateo; A Suhrbier; F A Lemonnier; P Langlade-Demoyen
Journal:  Eur J Immunol       Date:  1999-10       Impact factor: 5.532

6.  Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses.

Authors:  A Bhattacharjee; W G Richards; J Staunton; C Li; S Monti; P Vasa; C Ladd; J Beheshti; R Bueno; M Gillette; M Loda; G Weber; E J Mark; E S Lander; W Wong; B E Johnson; T R Golub; D J Sugarbaker; M Meyerson
Journal:  Proc Natl Acad Sci U S A       Date:  2001-11-13       Impact factor: 11.205

7.  Peptides derived from the onconeural HuD protein can elicit cytotoxic responses in HHD mouse and human.

Authors:  Anne Plonquet; Francisco Garcia-Pons; Eric Fernandez; Caramelle Philippe; Jeanine Marquet; Hélène Rouard; Marie Hélène Delfau-Larue; Konstantinos Kosmatopoulos; François Lemonnier; Jean Pierre Farcet; Romain K Gherardi; Pierre Langlade-Demoyen
Journal:  J Neuroimmunol       Date:  2003-09       Impact factor: 3.478

8.  Cytotoxic T cell activity against peptides of Hu protein in anti-Hu syndrome.

Authors:  Masami Tanaka; Yoshie Maruyama; Miho Sugie; Hitoshi Motizuki; Keiko Kamakura; Keiko Tanaka
Journal:  J Neurol Sci       Date:  2002-09-15       Impact factor: 3.181

9.  Adaptive immunity maintains occult cancer in an equilibrium state.

Authors:  Catherine M Koebel; William Vermi; Jeremy B Swann; Nadeen Zerafa; Scott J Rodig; Lloyd J Old; Mark J Smyth; Robert D Schreiber
Journal:  Nature       Date:  2007-11-18       Impact factor: 49.962

Review 10.  The immunobiology of cancer immunosurveillance and immunoediting.

Authors:  Gavin P Dunn; Lloyd J Old; Robert D Schreiber
Journal:  Immunity       Date:  2004-08       Impact factor: 31.745

View more
  32 in total

Review 1.  Small Cell Lung Cancer: Can Recent Advances in Biology and Molecular Biology Be Translated into Improved Outcomes?

Authors:  Paul A Bunn; John D Minna; Alexander Augustyn; Adi F Gazdar; Youcef Ouadah; Mark A Krasnow; Anton Berns; Elisabeth Brambilla; Natasha Rekhtman; Pierre P Massion; Matthew Niederst; Martin Peifer; Jun Yokota; Ramaswamy Govindan; John T Poirier; Lauren A Byers; Murry W Wynes; David G McFadden; David MacPherson; Christine L Hann; Anna F Farago; Caroline Dive; Beverly A Teicher; Craig D Peacock; Jane E Johnson; Melanie H Cobb; Hans-Guido Wendel; David Spigel; Julien Sage; Ping Yang; M Catherine Pietanza; Lee M Krug; John Heymach; Peter Ujhazy; Caicun Zhou; Koichi Goto; Afshin Dowlati; Camilla Laulund Christensen; Keunchil Park; Lawrence H Einhorn; Martin J Edelman; Giuseppe Giaccone; David E Gerber; Ravi Salgia; Taofeek Owonikoko; Shakun Malik; Niki Karachaliou; David R Gandara; Ben J Slotman; Fiona Blackhall; Glenwood Goss; Roman Thomas; Charles M Rudin; Fred R Hirsch
Journal:  J Thorac Oncol       Date:  2016-01-30       Impact factor: 15.609

2.  Three sensitive assays do not provide evidence for circulating HuD-specific T cells in the blood of patients with paraneoplastic neurological syndromes with anti-Hu antibodies.

Authors:  Adriaan H C de Jongste; Marieke T de Graaf; Emanuela Martinuzzi; Patricia D M van den Broek; Jaco Kraan; Cor H J Lamers; Roberto Mallone; Jan W Gratama; Peter A E Sillevis Smitt
Journal:  Neuro Oncol       Date:  2012-05-15       Impact factor: 12.300

3.  Immunotherapy in first line for extensive-stage small-cell lung cancer: another piece is going to fill the puzzle?

Authors:  Francesco Passiglia; Silvia Novello
Journal:  Ann Transl Med       Date:  2018-12

Review 4.  Immunologic privilege in the central nervous system and the blood-brain barrier.

Authors:  Leslie L Muldoon; Jorge I Alvarez; David J Begley; Ruben J Boado; Gregory J Del Zoppo; Nancy D Doolittle; Britta Engelhardt; John M Hallenbeck; Russell R Lonser; John R Ohlfest; Alexandre Prat; Maurizio Scarpa; Richard J Smeyne; Lester R Drewes; Edward A Neuwelt
Journal:  J Cereb Blood Flow Metab       Date:  2012-10-17       Impact factor: 6.200

Review 5.  Paraneoplastic syndromes associated with lung cancer.

Authors:  Nobuhiro Kanaji; Naoki Watanabe; Nobuyuki Kita; Shuji Bandoh; Akira Tadokoro; Tomoya Ishii; Hiroaki Dobashi; Takuya Matsunaga
Journal:  World J Clin Oncol       Date:  2014-08-10

6.  CD4+ and CD8+ T cells are both needed to induce paraneoplastic neurological disease in a mouse model.

Authors:  Christina Gebauer; Béatrice Pignolet; Lidia Yshii; Emilie Mauré; Jan Bauer; Roland Liblau
Journal:  Oncoimmunology       Date:  2016-12-09       Impact factor: 8.110

Review 7.  Novel therapies in small cell lung cancer.

Authors:  Hirva Mamdani; Raghava Induru; Shadia I Jalal
Journal:  Transl Lung Cancer Res       Date:  2015-10

Review 8.  Neuronal autoantigens--pathogenesis, associated disorders and antibody testing.

Authors:  Eric Lancaster; Josep Dalmau
Journal:  Nat Rev Neurol       Date:  2012-06-19       Impact factor: 42.937

Review 9.  Immune checkpoint inhibitors: making immunotherapy a reality for the treatment of lung cancer.

Authors:  Julie R Brahmer; Drew M Pardoll
Journal:  Cancer Immunol Res       Date:  2013-07-22       Impact factor: 11.151

Review 10.  Cellular and molecular biology of small cell lung cancer: an overview.

Authors:  Niki Karachaliou; Sara Pilotto; Chiara Lazzari; Emilio Bria; Filippo de Marinis; Rafael Rosell
Journal:  Transl Lung Cancer Res       Date:  2016-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.